BioElectronics Applies for FDA’s Opioid Alternative Innovation Challenge Program AUGUST 13, 2018 NEWS, PRESS RELEASES
IANWAR@BIELCORP.COM FREDERICK, MD, Aug. 13, 2018 (GLOBE NEWSWIRE) — BioElectronics Corporation (OTC PINK: BIEL), www.bielcorp.com, is pleased to announce that it has submitted an application to the U.S. Food and Drug Administration’s 2018 Opioid Innovation Challenge. This challenge was designed by the FDA to spur the development/deployment of medical devices that can help combat the opioid crisis by preventing/treating opioid use disorder. Click for FDA Challenge Website.
There are more than 245 million opioid prescriptions written annually in the US. BioElectronics’ products are FDA-cleared, nonprescription neuromodulation medical devices that provide pain therapy as an alternative to opioid medications.